Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 14;2010(4):CD007445.
doi: 10.1002/14651858.CD007445.pub2.

Chlorpromazine for psychosis induced aggression or agitation

Uzair Ahmed  1 , Hannah Jones, Clive E Adams
Affiliations

Chlorpromazine for psychosis induced aggression or agitation

Uzair Ahmed et al. Cochrane Database Syst Rev. .

Abstract

Background: Agitated or violent behaviour constitutes 10% of all emergency psychiatric treatment. Some guidelines do not recommend the use of chlorpromazine for rapid tranquillisation but it is still often used for this purpose.

Objectives: To examine the effects of oral or intramuscular chlorpromazine for psychosis induced agitation or aggression.

Search strategy: We searched the Cochrane Schizophrenia Group Trials Register (up to July 2009) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO.

Selection criteria: Randomised control trials or double blind trials (implying randomisation) comparing chlorpromazine with another drug or placebo for people who are thought to be acutely aggressive or agitated due to psychotic illness.

Data collection and analysis: We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a fixed-effects model.

Main results: One study (total n=30) met the inclusion criteria. When compared with haloperidol (Man 1973) (1 RCT, n=30) people allocated chlorpromazine were no more likely to have one additional injection than those allocated haloperidol (RR 3.00 CI 0.13 to 68.26). This remained true for 2-4 injections (RR 0.90 CI 0.52 to 1.55) and for 5 or more injections (RR 0.75 CI 0.20 to 2.79). Two people allocated chlorpromazine had sudden, serious hypotension while no one allocated haloperidol had such an effect (RR 5.00 CI 0.26 to 96.13). No extrapyramidal symptoms were observed. One person allocated chlorpromazine developed status epilepticus (RR 3.00 CI 0.13 to 68.26).

Authors' conclusions: Overall the quality of evidence is limited, poor and dated. Where drugs that have been better evaluated are available, it may be best to avoid use of chlorpromazine. Where chlorpromazine is used for acute aggression or where choices are limited, relevant trials are possible and urgently needed.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 CHLORPROMAZINE vs HALOPERIDOL, Outcome 1 Global outcome: number of additional injections.
1.2
1.2. Analysis
Comparison 1 CHLORPROMAZINE vs HALOPERIDOL, Outcome 2 Adverse effects.
1.3
1.3. Analysis
Comparison 1 CHLORPROMAZINE vs HALOPERIDOL, Outcome 3 Leaving the study early.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Man 1973 {published data only}
    1. Man PL, Chen CH. Rapid tranqulization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine. Psychosomatics 1973;14(1):59‐63. - PubMed

References to studies excluded from this review

Abse 1960 {published data only}
    1. Abse WD, Dahlstrom WG, Tolley AG. Evaluation of tranquilizing drugs in the management of acute mental disturbance. American Journal of Psychiatry 1960;117:973‐80. - PubMed
Chen 2004 {published data only}
    1. Chen M, Liu D, Lin J. The comparison study on curing agitation by haloperidol and chlorpromazine venoclysis. Medical Journal of Chinese People Health 2004;16(10):599.
Claghorn 1967 {published data only}
    1. Claghorn JL, Schoolar J C, Kinross‐Wright J. Pinoxepin vs chlorpromazine: A double‐blind comparison. Current Therapeutic Research 1967;9(8):434‐6. - PubMed
Hanlon 1965 {published data only}
    1. Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative effectiveness of eight phenothiazines. Psychopharmacology 1965;7(2):89‐106. - PubMed
Herrera 1988 {published data only}
    1. Herrera JN, Sramek JJ, Costa JF, Roy S, Heh CW, Nguyen BN. High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Diseases 1988;176(9):558‐61. - PubMed
Schiele 1961 {published data only}
    1. Schiele BC, Vestre ND. A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: A double blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychology 1961;22(3):151‐62. - PubMed
Somerville 1960 {published data only}
    1. Somerville DM, Cohen PH, Graves GD. Phenothiazine side effects. Comparison of two major tranquillizers. Journal of Mental Sciences 1960;106:1417‐24.
Stabenau 1964 {published data only}
    1. Stabenau JR, Grinols DR. A double blind comparison of thioridazine and chlorpromazine. Psychiatric Quarterly 1964;34(1):42‐63. - PubMed
Talbot 1964 {published data only}
    1. Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. American Journal of Psychiatry 1964;121:597‐600. - PubMed
Van Wyk 1971 {published data only}
    1. Wyk AJ, Marais GFT. Chlorpromazine, clotiapine and thioridazine ‐ A comparative clinical trial on bantu psychotic patients. South African Medical Journal 1971;45(34):945‐7. - PubMed
Wadzisz 1969 {published data only}
    1. Wadzisz FJ. A comparative trial of oxypertine and chlorpromazine in the treatment of acute psychoses. Current Therapeutic Research, Clinical and Experimental 1969;11(12):784‐92. - PubMed

Additional references

Alexander 2004
    1. Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry 2004;185:63‐9. [PUBMED: 15231557] - PubMed
Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. - PMC - PubMed
Bazier 2007
    1. Bazier S. Psychotropic drug directory. Stockport, UK: HealthComm UK Limited, 2007.
Belgamwar 2005
    1. Belgamwar RB, Fenton M. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003729.pub2] - DOI - PMC - PubMed
Bland 1997
    1. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
BNF 2008
    1. British National Formulary. British National Formulary. 55. NHS, London: Pharmaceutical Press, March 2008.
Chakrabarti 2007
    1. Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD001943.pub2] - DOI - PMC - PubMed
CIA 2008
    1. Central Intelligence Agency. The World Factbook. https://www.cia.gov/library/publications/the‐world‐factbook/ (accessed 21st July 2008).
Cunnane 1994
    1. Cunnane JG. Drug management of disturbed behaviour by psychiatrists. Psychiatric Bulletin 1994;18:138‐9.
Divine 1992
    1. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder CSO. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;13:629‐34. - PMC - PubMed
Elbourne 2002
    1. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Gibson 2004
    1. Gibson RC, Fenton M, Coutinho ES, Campbell C. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD000525.pub2] - DOI - PubMed
Gulliford 1999
    1. Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83. - PubMed
Higgins 2002
    1. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for systematic reviews of interventions 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org 2005.
Huf 2007
    1. Huf G, Coutinho ES, Adams CE. Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine. BMJ 2007;335(7625):869. [PUBMED: 17954515] - PMC - PubMed
Huf 2009
    1. Huf G, Alexander J, Allen MH, Raveendran NS. Haloperidol plus promethazine for psychosis‐induced aggression. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD005146] - DOI - PubMed
Kalyana 2006
    1. Kalyana Z, Bezchlibnky‐Butler J, Jefferies J. Clinical Handbook of Psychotropic Drugs. 16th Edition. New York, London: Hogrefe & Huber, 2006.
Keltner 2001
    1. Keltner NL, Folke DG. Psychotropic Drugs. 3rd Edition. St Louis, Missouri: Mosby, 2001.
Leucht 2008
    1. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WL. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2] - DOI - PMC - PubMed
Lopez‐Munez 2005
    1. Lopez‐Munez F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry 2005;17(3):113‐35. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Moher 2001
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomised trials. Lancet 2001;357(9263):1191‐94. - PubMed
Muralidharan 2006
    1. Muralidharan S, Fenton M. Containment strategies for people with serious mental illness. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD002084.pub2] - DOI - PMC - PubMed
NHS 2008
    1. NHS Business Services Authority. Prescription Pricing Division. http://www.ppa.org.uk/ppa/ppa_main.htm (accessed 21st July 2008).
NICE 2005
    1. National Collaborating Centre for Nursing and Supportive Care. The short‐term management of disturbed/violent behaviour in in‐patient psychiatric settings and emergency departments. http://www.nice.org.uk/Guidance/CG25/NiceGuidance/pdf/English (accessed August 2008).
Raveendran 2007
    1. Raveendran NS, Tharyan P, Alexander J, Adams CE. Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine. BMJ 2007;335(7625):865. [PUBMED: 17954514] - PMC - PubMed
Sailas 2000
    1. Sailas E, Fenton M. Seclusion and restraint for people with serious mental illnesses. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001163] - DOI - PMC - PubMed
Sartorius 1972
    1. Sartorius N, Shapiro R, Kimura M, Barrett K. WHO international pilot study of schizophrenia. Psychological Medicine 1972;2(4):422‐5. [PUBMED: 4656537] - PubMed
Seaman 2004
    1. Seaman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 2004;1(2):133‐52. - PubMed
Shah 2000
    1. Shah A, Jenkins R. Mental health economic studies from developing countries reviewed in the context of those from developed countries. Acta Psychiatrica Scandinavica 2000;101(2):87‐103. - PubMed
Swanson 1990
    1. Swanson J, Hozler C, Ganju VR. Violence and psychiatric disorder in the community: evidence from the epidemiologic catchment area surveys. Hospital and Community Psychiatry 1990;41:761‐70. - PubMed
Tardiff 1982
    1. Tardiff K, Sweillam A. Assaultive behavior among chronic inpatients. American Journal of Psychiatry 1982;139:212‐5. - PubMed
TREC 2003
    1. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. BMJ 2003;327(7417):708‐13. [PUBMED: 14512476] - PMC - PubMed
Turner 2007
    1. Turner T. Chlorpromazine: unlocking psychosis. BMJ 2007;334(Suppl 1):s7. [PUBMED: 17204765] - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75. - PubMed
Volz 2007
    1. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006391] - DOI - PubMed
WHO 2007
    1. World Health Organisation. WHO Essential Medicines List. 15th Edition. Geneva: World Health Organization, 2007.
WPA 2003
    1. World Psychiatric Association. The usefulness and use of second‐generation antipsychotic medications (An update of the review of evidence and recommendations by a task force of the World Psychiatric Association). http://www.peoplewho.org/documents/WPA2ndgenanti‐pDOC.doc. Yokohama, Japan, (Accessed 21st July 2008).

Publication types

MeSH terms

LinkOut - more resources